Several malaria vaccine candidates have been tested in malaria endemic countries [2], including the pre-erythrocyte vaccine RTS,S/AS02A, a recombinant polypeptide developed by GSK Biologicals that contains most of the C-terminal half of the circumsporozoite protein (CSP) sequence of P. falciparum fused to hepatitis B virus surface antigen formulated in the AS02A adjuvant system [3,4]. The gene discussed is DNAJC5; the disease is malaria.